基于移植后环磷酰胺方案受者停用来特莫韦后巨细胞病毒感染的模式
本研究在294例接受基于移植后环磷酰胺(PT-Cy)方案异基因造血细胞移植的受者中,分析停用来特莫韦后临床显著巨细胞病毒感染(csCMVi)的预测因素;80例完成预防且无csCMVi后停药者中,停药后90天csCMVi累积发生率为23.0%(95%CI 14.3-32.8),停用前低丙种球蛋白血症可预测csCMVi(HR 0.33;95%CI 0.12-0.93;P=.03),而T细胞和B细胞重建无预测作用。
要点
- 停用来特莫韦后90天csCMVi累积发生率为23.0%(95%CI 14.3-32.8),无巨细胞病毒终末器官疾病发生。
- 停用前低丙种球蛋白血症可预测csCMVi(HR 0.33;95%CI 0.12-0.93;P=.03)。
- 停用前T细胞和B细胞重建对csCMVi无预测作用;发生csCMVi者停用前自然杀伤细胞数更高(中位数202 vs 160;P=.03)。
核心结论
- 在基于PT-Cy方案移植的CMV血清阳性受者中,尽管来特莫韦暴露时间延长,停用来特莫韦后csCMVi仍较常见。
- 作者认为,对持续低丙种球蛋白血症患者增强CMV特异性适应性免疫是减少停用来特莫韦后csCMVi的合理路径。
研究设计与样本
- 本研究为观察性研究,纳入294例接受基于PT-Cy方案异基因造血细胞移植的受者,其中157例为CMV血清阳性,80例完成来特莫韦预防且无csCMVi后停药。
主要发现
- 来特莫韦暴露中位时间为203天(四分位距160-250天)。
- 停用来特莫韦后90天csCMVi累积发生率为23.0%(95%CI 14.3-32.8),无CMV终末器官疾病发生。
- 停用来特莫韦前低丙种球蛋白血症可预测csCMVi(HR 0.33;95%CI 0.12-0.93;P=.03)。
- 停用来特莫韦前T细胞和B细胞重建对csCMVi无预测作用。
- 发生csCMVi者停用来特莫韦前自然杀伤细胞数更高(中位数202 vs 160;P=.03)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Reactivation of latent cytomegalovirus (CMV) is increased in recipients of allogeneic hematopoietic cell transplantation (allo-HCT) with seropositive CMV using posttransplant cyclophosphamide (PT-Cy)-based graft-versus-host disease (GVHD) prophylaxis. Letermovir, a novel DNA terminase complex inhibitor, reduces the incidence of clinically significant CMV infection (csCMVi) in this population; however, parameters that predict csCMVi after letermovir withdrawal are not well described. Here, we examined clinical and immunological parameters in 294 recipients of PT-Cy-based allo-HCT, including 157 patients with CMV, of whom 80 completed letermovir prophylaxis without csCMVi and subsequently stopped letermovir. In this population, the median duration of letermovir exposure was 203 days (interquartile range [IQR], 160-250 days). After letermovir withdrawal, the 90-day cumulative incidence of csCMVi was 23.0% (95% confidence interval, 14.3-32.8). There were no episodes of CMV end-organ disease. Hypogammaglobulinemia before letermovir discontinuation was predictive of csCMVi (hazard ratio, 0.33; 95% confidence interval, 0.12-0.93; P = .03), whereas T-cell and B-cell reconstitution before letermovir withdrawal were not predictive of csCMVi. Higher numbers of natural killer cells were found before letermovir withdrawal in patients who experienced csCMVi (median, 202 vs 160; P = .03). In recipients with seropositive CMV, CD3+CD4-CD8+ T-cell reconstitution was faster in patients with CMV regardless of letermovir exposure. Taken together, these data suggest that csCMVi after letermovir withdrawal was frequent in patients treated with PT-Cy, despite prolonged exposure. Strategies to boost CMV-specific adaptive immunity in patients with persistent hypogammaglobulinemia is a logical pathway to reduce csCMVi after letermovir withdrawal.
引用
- Lin A, Brown S, Chinapen S, et al. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide-based transplant. Blood Adv. 2023. PMID: 37906513. doi:10.1182/bloodadvances.2023010966
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。